Christoph Kamm

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6041154/publications.pdf

Version: 2024-02-01

		687220	752573
21	864	13	20
papers	citations	h-index	g-index

21	21	21	1478
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Validity and reliability of the German multidimensional fatigue inventory in spinal muscular atrophy. Annals of Clinical and Translational Neurology, 2022, 9, 351-362.	1.7	5
2	Neues zur Genetik von Dystonien: Mutationen in den Genen VPS16 und VPS41 als Ursache einer Dystonie mit BeeintrÃchtigung der Fusion lysosomaler Vesikel. DGNeurologie, 2021, 4, 56-57.	0.0	0
3	Serum creatine kinase and creatinine in adult spinal muscular atrophy under nusinersen treatment. Annals of Clinical and Translational Neurology, 2021, 8, 1049-1063.	1.7	29
4	The ARCA Registry: A Collaborative Global Platform for Advancing Trial Readiness in Autosomal Recessive Cerebellar Ataxias. Frontiers in Neurology, 2021, 12, 677551.	1.1	15
5	Nusinersen in adults with 5q spinal muscular atrophy: a non-interventional, multicentre, observational cohort study. Lancet Neurology, The, 2020, 19, 317-325.	4.9	196
6	Prominent White Matter Involvement in Multiple System Atrophy of Cerebellar Type. Movement Disorders, 2020, 35, 816-824.	2.2	15
7	Frequency and risk factors of antibody-induced secondary failure of botulinum neurotoxin therapy. Neurology, 2020, 94, e2109-e2120.	1.5	31
8	Patient-Reported Prevalence of Non-motor Symptoms Is Low in Adult Patients Suffering From 5q Spinal Muscular Atrophy. Frontiers in Neurology, 2019, 10, 1098.	1.1	12
9	Validation of a selfâ€completed Dystonia Nonâ€Motor Symptoms Questionnaire. Annals of Clinical and Translational Neurology, 2019, 6, 2054-2065.	1.7	20
10	A novel heterozygous variant in ERLIN2 causes autosomal dominant pure hereditary spastic paraplegia. European Journal of Neurology, 2018, 25, 943.	1.7	27
11	Long-Term Effect of GPi-DBS in a Patient With Generalized Dystonia Due to GLUT1 Deficiency Syndrome. Frontiers in Neurology, 2018, 9, 381.	1.1	3
12	Clinical and genetic characteristics of sporadic adult-onset degenerative ataxia. Neurology, 2017, 89, 1043-1049.	1.5	45
13	Hereditary spastic paraplegia: Clinicogenetic lessons from 608 patients. Annals of Neurology, 2016, 79, 646-658.	2.8	218
14	New clinical insights into combined central and peripheral demyelination (CCPD). Journal of the Neurological Sciences, 2016, 364, 27-28.	0.3	3
15	The role of mutations in COL6A3 in isolated dystonia. Journal of Neurology, 2016, 263, 730-734.	1.8	15
16	Secondary antibody-induced treatment failure under therapy with incobotulinumtoxinA (XeominÂ®) in a patient with segmental dystonia pretreated with abobotulinumtoxinA (DysportÂ®). Journal of the Neurological Sciences, 2015, 350, 110-111.	0.3	7
17	Novel GNAL mutations in two German patients with sporadic dystonia. Movement Disorders, 2014, 29, 1833-1834.	2.2	18
18	Identification and functional analysis of novel THAP1 mutations. European Journal of Human Genetics, 2012, 20, 171-175.	1.4	48

#	Article	IF	Citations
19	Autoimmune disorders affecting both the central and peripheral nervous system. Autoimmunity Reviews, 2012, 11, 196-202.	2.5	74
20	No evidence for THAP1/DYT6 variants as disease modifiers in DYT1 dystonia. Movement Disorders, 2011, 26, 2136-2137.	2.2	10
21	SUSCEPTIBILITY TO DYT1 DYSTONIA IN EUROPEAN PATIENTS IS MODIFIED BY THE D216H POLYMORPHISM. Neurology, 2008, 70, 2261-2262.	1.5	73